- Home
- ADT vs NUVL Comparison
ADT vs NUVL Comparison
Compare ADT & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADT
- NUVL
- Stock Information
- Founded
- ADT 1874
- NUVL 2017
- Country
- ADT United States
- NUVL United States
- Employees
- ADT N/A
- NUVL N/A
- Industry
- ADT Diversified Commercial Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- ADT Consumer Discretionary
- NUVL Health Care
- Exchange
- ADT Nasdaq
- NUVL Nasdaq
- Market Cap
- ADT 7.1B
- NUVL 6.5B
- IPO Year
- ADT 2018
- NUVL 2021
- Fundamental
- Price
- ADT $8.84
- NUVL $99.32
- Analyst Decision
- ADT Buy
- NUVL Strong Buy
- Analyst Count
- ADT 5
- NUVL 12
- Target Price
- ADT $9.34
- NUVL $123.33
- AVG Volume (30 Days)
- ADT 6.3M
- NUVL 573.5K
- Earning Date
- ADT 11-04-2025
- NUVL 10-30-2025
- Dividend Yield
- ADT 2.52%
- NUVL N/A
- EPS Growth
- ADT N/A
- NUVL N/A
- EPS
- ADT 0.68
- NUVL N/A
- Revenue
- ADT $5,058,741,000.00
- NUVL N/A
- Revenue This Year
- ADT $6.22
- NUVL N/A
- Revenue Next Year
- ADT $4.32
- NUVL N/A
- P/E Ratio
- ADT $12.67
- NUVL N/A
- Revenue Growth
- ADT 6.58
- NUVL N/A
- 52 Week Low
- ADT $6.71
- NUVL $55.54
- 52 Week High
- ADT $8.94
- NUVL $104.90
- Technical
- Relative Strength Index (RSI)
- ADT 58.02
- NUVL 62.23
- Support Level
- ADT $8.54
- NUVL $90.00
- Resistance Level
- ADT $8.85
- NUVL $104.90
- Average True Range (ATR)
- ADT 0.13
- NUVL 5.19
- MACD
- ADT 0.02
- NUVL 0.53
- Stochastic Oscillator
- ADT 95.12
- NUVL 72.49
About ADT ADT Inc.
ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name. The company segments include Consumer and Small Business (CSB).
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.